Supplementary Table 3. Sensitivity analysis on the effect modification by TBIL with additional adjustment of eGFR, hsCRP, and salt intake in models

Outcome	Group	N	n (%)	Adj. OR/cOR (95% CI)*	*P*	*P* for interaction
Presence of CSVD (Wardlaw)†	Participants with TBIL ≤17 μmol/L					
	No hypertension	1,276	258 (20.2)	Ref.		0.034
	Hypertension	943	389 (41.3)	1.87 (1.42–2.48)	<0.001	
	Participants with TBIL >17 μmol/L					
	No hypertension	468	129 (27.6)	Ref.		
	Hypertension	374	158 (42.3)	1.05 (0.67–1.63)	0.837	
Presence of CSVD (Rothwell)†	Participants with TBIL ≤17 μmol/L					
	No hypertension	1,276	391 (30.6)	Ref.		0.026
	Hypertension	943	514 (54.5)	1.86 (1.43–2.40)	<0.001	
	Participants with TBIL >17 μmol/L					
	No hypertension	468	171 (36.5)	Ref.		
	Hypertension	374	195 (52.1)	1.05 (0.69–1.60)	0.816	
Total CSVD burden (Wardlaw)‡	Participants with TBIL ≤17 μmol/L					
	No hypertension	1,276		Ref.		0.082
	Hypertension	943		1.89 (1.44–2.48)	<0.001	
	Participants with TBIL >17 μmol/L					
	No hypertension	468		Ref.		
	Hypertension	374		1.20 (0.78–1.84)	0.400	
Modified total CSVD burden (Rothwell)‡	Participants with TBIL ≤17 μmol/L					
	No hypertension	1,276		Ref.		0.048
	Hypertension	943		1.86 (1.45–2.38)	<0.001	
	Participants with TBIL >17 μmol/L					
	No hypertension	468		Ref.		
	Hypertension	374		1.16 (0.78–1.73)	0.466	

All models were adjusted for age, sex, body mass index, current smoking, current drinking, diabetes, dyslipidemia, antihypertensive medication, antiplatelet medication, anticoagulant medication, alanine aminotransferase, aspartate aminotransferase, eGFR, hsCRP, and habit of salt intake.
TBIL, total bilirubin; eGFR, estimated glomerular filtration rate; hsCRP, high-sensitivity C-reactive protein; Adj., adjust; OR, odds ratio; cOR, common odds ratio; CI, confidence interval; CSVD, cerebral small vessel disease; Ref., reference.
*The association of hypertension with the presence of CSVD was evaluated using OR, while with CSVD burden was evaluated using cOR. The product term of the hypertension state and TBIL group was included in the model to assess the effect modification by TBIL; †Presence of CSVD was defined as total CSVD or modified total CSVD burden scores ≥1; ‡Total and modified total CSVD burdens were classified as grade 0 (total or modified total CSVD burden score 0), grade 1 (total or modified total CSVD burden score 1), grade 2 (total or modified total CSVD burden score 2–3), or grade 3 (total or modified total CSVD burden score ≥4).